Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Fig. 6

T-PNU promotes long-lasting immune protection. a, Outline of a representative rechallenge experiment. b, EMT6-hHER2 tumor-free animals after T-PNU treatment were rechallenged with EMT6-hHER2, EMT6-WT and TS/A Thy1.1 cancer cells. P-value < 0.0005 *** (Gehan-Breslow-Wilcoxon Test). c, Tumor growth of untreated controls. d, Overall survival curves of b and c

Back to article page